OCA
Octagon Capital Advisors’s Apellis Pharmaceuticals APLS Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $15.6M | Sell |
903,500
-1,190,500
| -57% | -$20.6M | 3.43% | 12 |
|
|
2025
Q1 | $45.8M | Sell |
2,094,000
-912,980
| -30% | -$20M | 8.86% | 2 |
|
|
2024
Q4 | $96M | Hold |
3,006,980
| – | – | 15.79% | 1 |
|
|
2024
Q3 | $86.7M | Buy |
3,006,980
+126,100
| +4% | +$3.64M | 13.49% | 1 |
|
|
2024
Q2 | $111M | Buy |
2,880,880
+73,900
| +3% | +$2.83M | 17.37% | 1 |
|
|
2024
Q1 | $165M | Hold |
2,806,980
| – | – | 19.77% | 1 |
|
|
2023
Q4 | $168M | Sell |
2,806,980
-323,020
| -10% | -$19.3M | 26.88% | 1 |
|
|
2023
Q3 | $119M | Buy |
3,130,000
+511,700
| +20% | +$19.5M | 18.29% | 1 |
|
|
2023
Q2 | $239M | Sell |
2,618,300
-631,700
| -19% | -$57.5M | 33.19% | 1 |
|
|
2023
Q1 | $214M | Buy |
3,250,000
+90,000
| +3% | +$5.94M | 30.84% | 1 |
|
|
2022
Q4 | $163M | Buy |
3,160,000
+656,941
| +26% | +$34M | 25.44% | 1 |
|
|
2022
Q3 | $171M | Sell |
2,503,059
-80,000
| -3% | -$5.46M | 29.5% | 1 |
|
|
2022
Q2 | $117M | Buy |
2,583,059
+243,000
| +10% | +$11M | 31.17% | 1 |
|
|
2022
Q1 | $119M | Buy |
2,340,059
+319,148
| +16% | +$16.2M | 25.7% | 1 |
|
|
2021
Q4 | $95.5M | Buy |
2,020,911
+425,000
| +27% | +$20.1M | 18.59% | 1 |
|
|
2021
Q3 | $52.6M | Buy |
1,595,911
+339,646
| +27% | +$11.2M | 12.95% | 2 |
|
|
2021
Q2 | $79.4M | Buy |
1,256,265
+707,891
| +129% | +$44.7M | 16.44% | 1 |
|
|
2021
Q1 | $23.5M | Hold |
548,374
| – | – | 8.86% | 3 |
|
|
2020
Q4 | $31.4M | Buy |
+548,374
| New | +$31.4M | 10.87% | 1 |
|